Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report published on Tuesday,Benzinga reports. They currently have a $70.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Stock Up 0.9 %

HALO stock opened at $56.77 on Tuesday. The business’s fifty day moving average price is $51.00 and its two-hundred day moving average price is $54.35. The stock has a market capitalization of $7.22 billion, a price-to-earnings ratio of 18.80, a PEG ratio of 0.43 and a beta of 1.25. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Hussman Strategic Advisors Inc. grew its position in Halozyme Therapeutics by 75.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 73,500 shares of the biopharmaceutical company’s stock worth $3,514,000 after acquiring an additional 31,500 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of Halozyme Therapeutics by 23.8% during the fourth quarter. Private Advisor Group LLC now owns 29,908 shares of the biopharmaceutical company’s stock worth $1,430,000 after purchasing an additional 5,745 shares during the last quarter. Convergence Investment Partners LLC increased its stake in shares of Halozyme Therapeutics by 25.9% in the fourth quarter. Convergence Investment Partners LLC now owns 34,713 shares of the biopharmaceutical company’s stock valued at $1,660,000 after buying an additional 7,151 shares during the period. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $69,000. Finally, State of New Jersey Common Pension Fund D boosted its position in Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after buying an additional 302 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.